×
About 47,170 results

ALLMedicine™ Gastric Cancer Center

Research & Reviews  16,349 results

The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti...
https://doi.org/10.1007/s00262-022-03240-2 10.1016/j.immuni.2016.04.023 10.1038/nrc.2016.36 10.1158/1078-0432.Ccr-13-3271 10.1056/NEJMoa1200690 10.1016/s0140-6736(17)31827-5 10.1073/pnas.1705327114 10.1158/1078-0432.Ccr-18-1449 10.1007/s00262-018-2225-x 10.3389/fimmu.2018.00014 10.4049/jimmunol.178.7.4112 10.1084/jem.186.9.1407 10.1084/jem.20030235 10.1002/eji.200525983 10.1002/cyto.a.20643 10.1016/j.bbrc.2016.08.115 10.1093/jjco/hyaa202 10.1001/jamaoncol.2018.0013 10.1016/s0140-6736(18)31257-1 10.1001/jamaoncol.2020.3370 10.1007/s10120-016-0631-3 10.1016/s1470-2045(20)30169-8 10.1038/nri.2015.3 10.1158/0008-5472.Can-15-1545 10.1038/s41416-020-0813-y 10.1186/s40425-018-0399-6 10.1158/1078-0432.Ccr-13-1877 10.4049/jimmunol.1402711 10.1016/j.cellimm.2018.02.002 10.1158/1078-0432.Ccr-17-2257 10.1016/j.ctrv.2016.11.007 10.1126/science.aaa1348 10.1056/NEJMoa1406498 10.1038/s41467-018-05072-0 10.1158/1078-0432.Ccr-13-0945 10.1002/ijc.26297 10.1158/2326-6066.Cir-14-0239 10.1186/s13059-019-1921-y 10.1038/nm.4051 10.1080/25785826.2019.1698261 10.1158/2326-6066.Cir-15-0210 10.1093/intimm/dxx073 10.1038/s41586-021-03752-4
Cancer Immunology, Immunotherapy : CII; Nose Y, Saito T et. al.

Jul 2nd, 2022 - Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death pro...

Nutritional screening in a cancer prehabilitation programme: A cohort study.
https://doi.org/10.1111/jhn.13057
Journal of Human Nutrition and Dietetics : the Official J... Burden ST, Bibby N et. al.

Jul 2nd, 2022 - Cancer patients are often malnourished pre-operatively. Study aims were to establish if current screening was appropriate for use in prehabilitation and investigate any association between nutritional risk, functionality and quality of life (QoL)....

Causal effect of autoimmune liver diseases on cancer: meta-analyses of cohort studies a...
https://doi.org/10.1111/liv.15355
Liver International : Official Journal of the Internation... Gu D, Zhang M et. al.

Jul 2nd, 2022 - Prior studies suggested that patients with autoimmune liver diseases (AiLD) had an increased risk of cancer, wheras the causal effect remained unclear. Meta-analyses concerning the relationship between AiLD and cancer risk were performed to calcul...

Meta-analysis of the relationship between lymphovascular invasion and prognosis of pati...
https://doi.org/10.1097/MD.0000000000029798
Medicine Li D, Li W et. al.

Jul 2nd, 2022 - Lymphovascular invasion is considered to be a high-risk pathological feature after radical resection of gastric cancer, but the relationship between lymphovascular invasion and the prognosis of stage I gastric cancer is still controversial. Theref...

see more →

Guidelines  23 results

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0008
Journal of the National Comprehensive Cancer Network : JN... Ajani JA, D'Amico TA et. al.

Feb 8th, 2022 - Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor p...

ACR Appropriateness Criteria® Epigastric Pain.
https://doi.org/10.1016/j.jacr.2021.08.006
Journal of the American College of Radiology : JACR; , Vij A et. al.

Nov 20th, 2021 - Epigastric pain can have multiple etiologies including myocardial infarction, pancreatitis, acute aortic syndromes, gastroesophageal reflux disease, esophagitis, peptic ulcer disease, gastritis, duodenal ulcer disease, gastric cancer, and hiatal h...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Hereditary diffuse gastric cancer: updated clinical practice guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116190
The Lancet. Oncology; Blair VR, McLeod M et. al.

Aug 8th, 2020 - Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour...

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
https://doi.org/10.1097/AOG.0000000000003562
Obstetrics and Gynecology;

Nov 26th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,710 results

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
https://clinicaltrials.gov/ct2/show/NCT03472365

Jul 1st, 2022 - Approximately 110 participants will be assigned to SHR-1210 + capecitabine + oxaliplatin combination therapy (Cohort 1), or SHR-1210 + apatinib combination therapy (Cohort 2).

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
https://clinicaltrials.gov/ct2/show/NCT04535414

Jul 1st, 2022 - Background: Hereditary Diffuse Gastric Cancer (HDGC) is most often attributed to inactivating germline mutations in the E-cadherin (CDH1) tumor suppressor gene. Mutation carriers have a 24-70% lifetime risk of developing gastric adenocarcinoma. In...

Esophageal Cancer in Northeastern Iran
https://clinicaltrials.gov/ct2/show/NCT00450788

Jul 1st, 2022 - Esophageal cancer is the sixth most common cause of cancer death worldwide, killing over 380,000 people each year. Over 80% of esophageal cancers occur in developing countries, where the great majority of cases are squamous cell carcinomas. Esopha...

Pazopanib and ARQ 197 for Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01468922

Jul 1st, 2022 - Background: Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) signal transduction pathways have synergistic effects on promoting angiogenesis and growth factor expression. Hypoxia caused by treatment with VEGF inhibitors...

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
https://clinicaltrials.gov/ct2/show/NCT03030404

Jul 1st, 2022 - Background: An estimated 1-3% of gastric cancer cases occur within a familial background as part of an inherited cancer syndrome. Hereditary Diffuse Gastric Cancer (HDGC) is the most frequent form of familial gastric cancer and has been linked to ...

see more →

News  775 results

Commentary: Ramucimumab, Napabucasin, and Pembrolizumab Trial Results, July 2022
https://www.mdedge.com/hematology-oncology/article/255995/gastrointestinal-cancer/commentary-ramucimumab-napabucasin-and
Nataliya Uboha, MD, PhD

Jul 1st, 2022 - Patients with advanced gastroesophageal adenocarcinoma (GEA) have a poor prognosis. Despite recent improvements in treatments, overall survival (OS) for most of these patients remains < 18 months.

Artificial intelligence may support the diagnosis of early gastric cancer
https://www.mdedge.com/hematology-oncology/article/255641/gastrointestinal-cancer/artificial-intelligence-may-support

Jun 22nd, 2022 - Key clinical point: Artificial intelligence (AI) shows high sensitivity, specificity, and accuracy for the diagnosis of early gastric cancer. Major finding: The pooled sensitivity and specificity of AI for early gastric cancer diagnosis were 0.

Nonmetastatic gastric cancer survival trends in the United States and Europe
https://www.mdedge.com/hematology-oncology/article/255639/gastrointestinal-cancer/nonmetastatic-gastric-cancer-survival

Jun 22nd, 2022 - Key clinical point: There is no improvement in survival of patients with nonmetastatic gastric adenocarcinoma in selected European countries. The survival has slightly improved in the US and worsened in Sweden.

Gastric cancer: Epstein-Barr virus and H. pylori coinfection is not prognostic
https://www.mdedge.com/hematology-oncology/article/255637/gastrointestinal-cancer/gastric-cancer-epstein-barr-virus-and-h

Jun 22nd, 2022 - Key clinical point: Epstein-Barr virus (EBV) and Helicobacter pylori coinfection is not an independent prognostic factor for gastric cancer. EBV infection was associated with survival, but not in patients with non-gastric carcinoma with lymphoid s.

see more →

Patient Education  7 results see all →